- Home
- LOMA vs COGT Comparison
LOMA vs COGT Comparison
Compare LOMA & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOMA
- COGT
- Stock Information
- Founded
- LOMA 1926
- COGT 2014
- Country
- LOMA Argentina
- COGT United States
- Employees
- LOMA N/A
- COGT N/A
- Industry
- LOMA Building Materials
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- LOMA Industrials
- COGT Health Care
- Exchange
- LOMA Nasdaq
- COGT Nasdaq
- Market Cap
- LOMA 1.3B
- COGT 1.1B
- IPO Year
- LOMA 2017
- COGT 2018
- Fundamental
- Price
- LOMA $7.60
- COGT $12.66
- Analyst Decision
- LOMA Strong Buy
- COGT Strong Buy
- Analyst Count
- LOMA 2
- COGT 11
- Target Price
- LOMA $15.00
- COGT $21.20
- AVG Volume (30 Days)
- LOMA 707.0K
- COGT 1.5M
- Earning Date
- LOMA 11-05-2025
- COGT 11-11-2025
- Dividend Yield
- LOMA N/A
- COGT N/A
- EPS Growth
- LOMA N/A
- COGT N/A
- EPS
- LOMA 0.37
- COGT N/A
- Revenue
- LOMA $559,741,122.00
- COGT N/A
- Revenue This Year
- LOMA $22.92
- COGT N/A
- Revenue Next Year
- LOMA $25.84
- COGT N/A
- P/E Ratio
- LOMA $21.22
- COGT N/A
- Revenue Growth
- LOMA N/A
- COGT N/A
- 52 Week Low
- LOMA $7.35
- COGT $3.72
- 52 Week High
- LOMA $14.17
- COGT $13.50
- Technical
- Relative Strength Index (RSI)
- LOMA 18.35
- COGT 58.36
- Support Level
- LOMA $7.71
- COGT $12.50
- Resistance Level
- LOMA $8.34
- COGT $13.50
- Average True Range (ATR)
- LOMA 0.44
- COGT 0.54
- MACD
- LOMA -0.15
- COGT -0.02
- Stochastic Oscillator
- LOMA 3.70
- COGT 51.45
About LOMA Loma Negra Compania Industrial Argentina Sociedad Anonima ADS
Loma Negra Cia Industria Argentina SA is a cement producer in Argentina. The company operates in five segments: Cement, masonry cement, and lime; Concrete; Rail services; Aggregates; and Others. The majority of its revenue derives from Cement, masonry cement, and lime segments.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.